1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Celltrion Pharm Inc

Celltrion Pharm Inc

068760.KS
Celltrion Pharm IncKR flagKorea Exchange
93,500.00
KRW
-600.00
- -
Celltrion Pharm Inc
068760.KS
(Korea Exchange)

Recent

price

93,500.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,180.27
2,507.45
2,454.03
2,444.27
3,205.17
2,561.04
2,829.46
3,073.66
3,314.89
3,918.64
5,369.24
8,984.6
8,701.12
8,757.55
10,770.01
12,347.05
12,552.93
Revenue per Share
189.56
185.21
185.59
121.29
281.86
-521.13
-569.77
61.42
-211.89
194.27
481.36
779.15
585.12
478.99
495.1
892
908.7
Basic EPS, GAAP
-731.09
-1,473.82
-3,942.41
-4,390.92
-851.18
-1,867.39
-834.6
-136.36
145.07
-94.87
-184.1
1,817.25
-232.87
41.86
1,140.6
1,576.93
1,183.33
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
652.85
935.99
1,140.66
1,140.62
1,569.79
-136.57
-540.06
-95.92
-635.76
635.35
1,137.23
1,894.13
2,480.47
2,958.19
3,455.4
4,420.97
4,024.01
Book Value per Share
5,169.73
5,039.09
6,023.5
5,670.82
7,573.12
5,260.35
6,376.33
5,740.01
5,285.89
5,503.06
6,034.53
6,591.66
7,110.36
7,599.31
8,062.94
9,040.59
8,431.66
Tangible Book Value per Share
18
19
19
22
21
29
37
44
44
44
44
44
44
44
44
43
44
Basic Weighted Avg Shares
40,219
46,494
46,968
52,657
66,744
74,732
104,811
135,860
146,880
173,513
233,568
398,738
386,040
388,794
477,835
536,400
555,998
Sales/Revenue/Turnover
15.14
14.47
10.81
14.23
12.51
-18.1
-14.32
6.38
2.43
8.49
10.12
11.99
9.89
9.28
7.79
10.46
10.48
Operating Margin (%)
2,380
1,647
1,160
1,050
1,187
4,442
12,069
12,234
12,712
13,023
13,470
16,378
17,419
19,725
20,093
22,249
23,192
Depreciation Expense
3,497
3,434
3,552
2,613
5,869
-15,207
-21,106
2,715
-9,389
8,602
20,940
34,579
25,960
21,265
21,966
38,752
40,248
Net Income, GAAP
35.68
2.7
- -
27.86
0.68
- -
- -
- -
- -
2.74
- -
18.68
14.8
18.86
26.19
22.05
22.69
Effective Tax Rate (%)
8.69
7.39
7.56
4.96
8.79
-20.35
-20.14
2
-6.39
4.96
8.97
8.67
6.72
5.47
4.6
7.22
7.24
Profit Margin (%)
64,962
46,935
34,237
114,273
34,864
36,860
99,455
86,816
54,926
39,717
46,027
71,226
99,920
115,485
144,023
186,976
188,857
Working Capital
30,594
32,757
64,065
165,570
84,401
114,089
89,000
48,125
34,375
38,811
57,851
39,398
21,823
5,862
15,089
16,560
15,441
LT Debt
121,805
128,268
157,246
168,412
214,426
192,314
276,706
293,624
270,035
280,031
300,561
331,969
356,787
376,666
396,922
435,963
434,821
Total Equity
2.89
4.13
- -
1.82
2.27
- -
- -
- -
- -
3.35
- -
7.72
6.28
5.51
4.93
7.42
7.65
Return on Invested Capital (%)
14.72
8.61
- -
2.29
4.34
- -
- -
- -
- -
8.87
- -
15.34
11.67
9.92
8.88
12.95
13.53
Return on Capital (%)
34.1
23.36
18.13
11.26
20.5
- -
- -
- -
- -
- -
53.97
51.79
26.75
17.62
15.43
22.44
23.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
153,526
144,755
145,140
LT Borrowings
- -
- -
- -
LT Finance Leases
17,223
16,560
15,441
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
44
44
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
464,496
470,598
481,571
Cash, Cash Equivalents & STI
122,762
116,929
133,914
Accounts Receivable, Net
204,845
220,287
209,060
Inventories
129,886
122,936
125,999
Total Current Liabilities
287,632
283,622
292,714
Payables & Accruals
- -
- -
- -
ST Debt
153,526
144,755
145,140
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.17%
7.74%
9.84%
Free Cash Flow
91.54%
264.11%
35.38%
Net Income, GAAP
-46.63%
20.37%
76.42%
Sales/Revenue/Turnover
23.41%
20.68%
12.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
96,969
117,155
128,130
135,582
477,835
2025
112,524
131,298
138,175
154,404
536,400
2026
132,122
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
41.08
120.45
178.34
- -
495.1
2025
161.76
250.36
258.71
- -
892
2026
199.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Nutra Pharma Corp. (NPHC)
Livzon Pharmaceutical Group Inc. (1513.HK)
Zomedica Corp. (ZOM)
Rua Bioscience Limited (RUA.NZ)
KPC Pharmaceuticals, Inc. (600422.SS)
IDT Australia Limited (IDT.AX)
Business
Celltrion Pharm Inc. functions within the South Korean healthcare industry, specializing in the development and commercialization of a broad spectrum of pharmaceutical products. The company's key operations encompass manufacturing and distributing both biosimilars and over-the-counter medications. Its diverse portfolio includes hepatotonics, analgesics, anti-inflammatory and antipyretic compounds, antihistamines, respiratory treatments, circulatory system drugs, digestive aids, hormone-related medications, various antibiotics and antimycotics, as well as nutritional supplements and tonics. Celltrion Pharm Inc. primarily supplies its offerings to university hospitals and local pharmacies across South Korea, with a growing presence in certain overseas markets like the Philippines and Kazakhstan. As a subsidiary of Celltrion, Inc., it also provides contract manufacturing services, leveraging facilities that meet global quality standards.